Lilly’s Omvoh meets primary endpoint in pediatric ulcerative colitis trial

Omvoh (mirikizumab-mrkz) met the primary endpoint of clinical remission in a Phase 3 pediatric ulcerative colitis study and is the first IL-23p19 inhibitor to report one-year Phase 3 results in the condition.